Sittner & Nelson’s ImmunityBio IBRX Stock Holding History

Sittner & Nelson’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.76K	Hold	1,000	–	–	﹤0.01%	457
2026 Q1	$7.67K	Hold	1,000	–	–	﹤0.01%	450
2025 Q4	$6.05K	Hold	1,000	–	–	﹤0.01%	430
2025 Q3	$2.46K	Buy	+1,000	New	+$2.58K	﹤0.01%	434

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sittner & Nelson's IBRX Position: Q2 2026 in Review

Sittner & Nelson held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,000 shares worth $8.76K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

Sittner & Nelson first reported a position in IBRX in Q3 2025 and has held it in 4 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Sittner & Nelson held 1,000 shares of ImmunityBio worth $8.76K as of Q2 2026.
Sittner & Nelson left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Sittner & Nelson's portfolio in Q2 2026, its #457 holding.
Sittner & Nelson first reported a position in ImmunityBio in Q3 2025 and has held it in 4 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Sittner & Nelson's 13F filing for Q2 2026, filed 7 Aug 2026.